France La Tronche

INSERM – DR Auvergne Rhone Alpes

Institute for Advanced Biosciences

Brief Overview

Formerly named Institut Albert Bonniot, the Institute for Advanced Biosciences is large joint center (19 teams, 5 platforms) of INSERM, CNRS and University Grenoble-Alpes. Its scientific strategy focuses on how environmental constraints (micro- and macro-) shape (epi)genomes and tissues during development and diseases. A central theme shared across teams is respiratory health, covering air quality and impact of air pollution, chronic respiratory diseases (asthma, COPD) and lung cancer. IAB deploys a multidisciplinary expertise scientific  from molecules to populations and encompassing genetics, epigenetics/signaling through chromatin, cell-matrix interactions, cell signaling, host-parasite interactions, immunology and environmental epidemiology.

Research Areas

Asthma\Cell biology\Epigenetics\Lung cancer\Molecular biology

Host center eligibility

Global fellowships (return phase only)\ European fellowships

Research infrastructure/facilities

IAB (300 researchers and clinicians) is located next to Grenoble University Hospital. It offers shared platforms covering a translational continuum from molecules to biomarkers and targets for clinical value. These platforms include: medical epigenetics (EpiMED), protein engineering (IngeProt), advanced cell imaging (MicroCell), metabolomics (GEMELI), preclinical animal models (Optimal). IAB researchers have constituted unique resources on respiratory health, including environmental cohorts (exposome studies, PI R SLAMA) and lung tumor and tissue banks and databases (PI: E BRAMBILLA, n=4000). IAB has a partnership with EMBL Grenoble on structural biology, supporting research on innovative drug targets.

Research funding/Resources

Of 19 IAB groups, 5 (60 staff)  are engaged in research on respiratory health: (1) S. KHOCHBIN (epigenetic reprograming in COPD/lung cancer); (2) B. EYMIN (lung cancer spliceosome as drug target in lung cancer); (3) JL. COLL (nanovectors for cancer therapy); (4) P. HAINAUT/E. BRAMBILLA (histomolecular classification of lung cancers, TP53 mutations) and (5) R. SLAMA/V. SIROUX (asthma in children, air pollution).

Funding include (1) H2020 ATHLETE (SIROUX, SLAMA, 12 M€), MSD-Avenir ERiCAN (HAINAUT, 2.1 M€), LIFE (Respiratory health trajectories, HAINAUT/KHOCHBIN/SIROUX, 2 M€), EIT-HEALTH PAPHOD AND PATIENTMINER (HAINAUT, total 1 M€), Canc’Air (ARC, Air pollution and epigenome), LEPEULE/KHOCHBIN (0.5M€).

Links to non-academic sector

IAB is operating within a dense ecosystem of innovation and value creation, considered as one of the most successful at national level. The main partners of IAB are Floralis (the innovation subsidiary of UGA), SATT Linksium, Inserm Transfer and Cancéropole CLARA. In addition, IAB has a  technology transfer manager who supports researchers for patents registration and startup creation. A total of 7 start-ups and 39 patents have been developed in 2015-20.

Experience hosting international researchers, career development & training programmes, outreach activities

IAB host researchers from 27 nationalities on all continents (20% of the staff). IAB develops an international strategy for attracting and promoting new talents, either though recruitment, mobility or promotion (call for new leaders in 2018-19 for example). IAB conducts training through research and hands-on practice and offers mentorship towards progression to independence. International mobility, multiculturality, equal opportunity and the values of laicity are actively promoted. IAB is open to all nationalities and operates in both French and English languages.

HR Excellence in Research – EU award